Mr. Andrew Rae reports

ICO THERAPEUTICS ANNOUNCES ORAL AMPHOTERICIN B CLINICAL ADVISORY BOARD

iCo Therapeutics Inc. has formed an oral amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.

Dr. Peter Hnik, chief medical officer, stated: "We look forward to working with our clinical advisers as we refine the design of mid-staged clinical studies for our oral amphotericin B candidate. We are fortunate to have two global experts in the anti-fungal arena advising iCo and look forward to additional appointments to this expert group."

Dr. Perfect, who has joined the iCo clinical advisory board, noted, "The development of an oral amphotericin B candidate could be a major step forward in the treatment of fungal and parasitic disease outside an acute-care setting."

Prof. John R. Perfect, MD, FIDSA

Dr. Perfect is a James B. Duke professor of medicine and is associated with Duke University, a professor of molecular genetics and microbiology, and chief of infectious diseases. His general research focus for four decades has been on cryptococcosis pathogenesis and management. He also investigates other fungal infections through translational and clinical trials. He interacts as a consultant for many pharmaceutical companies in the anti-fungal space. Along with his basic science research portfolio, he also attends to patients at the bedside. He is president of the Mycoses Study Group (MSG) based in the United States and president-elect of the International Society of Human and Animal Mycology (ISHAM).

Prof. David W. Denning, FRCP, FRCPath, FMedSci, FIDSA

Dr. Denning is an infectious diseases clinician with expertise in fungal diseases. He serves as the chief executive of the Global Action Fund for Fungal Infections (GAFFI) and professor of infectious diseases and global health at the University of Manchester, United Kingdom. Dr. Denning manages the National Aspergillosis Centre in Manchester, a referral centre in the United Kingdom for all patients with chronic pulmonary aspergillosis (annual budget: approximately seven million British pounds). The National Aspergillosis Centre was designated by the European Confederation of Medical Mycology as the first centre of excellence in clinical and laboratory mycology and clinical studies, achieving diamond status. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus, and getting new anti-fungals developed. He has published extensively (over 550 academic papers) and has a citation H-index of 113. He leads LIFE (Leading Internal Fungal Education, which is focused on improving patient outcomes through on-line education. He is the executive director of the Global Action Fund for Fungal Infections, based in Switzerland and the United Kingdom, which advocates for access to fungal diagnostics and anti-fungal therapies. He is the founder of two biotechnology companies -- F2G Ltd. (anti-fungal drug discovery and development in phase 2) and Myconostica Ltd. (now Lab21) for molecular diagnostic tests for fungi.

About iCo Therapeutics Inc.

iCo Therapeutics identifies existing development-stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the company's core focus areas, and, if so, the company will seek to capture further value through partnerships, such as its partnership with Immune Pharmaceuticals, which is in several phase 2 studies involving iCo-008.

We seek Safe Harbor.